Literature DB >> 15480699

[Photodynamic therapy in AMD. Strategy for indication].

D Pauleikhoff1, G Spital.   

Abstract

In recent years several prospective studies have dealt with the therapeutic possibilities of PDT. In consideration of lesion size and its composition, a subtly differentiated scheme of therapy has been developed. Based on essential studies, recommendations on the indication for photodynamic therapy are summarized. They are complemented by references to safety and efficacy of photodynamic therapy. Users of PDT are given a short summary of relevant studies with current recommendations, which might ease the daily procedure of indicating photodynamic therapy.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15480699     DOI： 10.1007/s00347-004-1119-9

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


  8 in total

1.  [Photodynamic therapy: extended indication].

Authors:  R Müller-Velten; St Michels; U Schmidt-Erfurth; H Laqua
Journal:  Ophthalmologe       Date:  2003-05       Impact factor: 1.059

2.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2.

Authors:  Neil M Bressler
Journal:  Am J Ophthalmol       Date:  2002-01       Impact factor: 5.258

3.  Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.

Authors:  Neil M Bressler; Jennifer Arnold; Mustapha Benchaboune; Mark S Blumenkranz; Gary E Fish; Evangelos S Gragoudas; Hilel Lewis; Ursula Schmidt-Erfurth; Jason S Slakter; Susan B Bressler; Kelly Manos; Yong Hao; Laurie Hayes; John Koester; Al Reaves; H Andrew Strong
Journal:  Arch Ophthalmol       Date:  2002-11

4.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

5.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

Authors:  N M Bressler
Journal:  Arch Ophthalmol       Date:  2001-02

6.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4.

Authors:  Mohammad Azab; Mustapha Benchaboune; Kevin J Blinder; Neil M Bressler; Susan B Bressler; Evangelos S Gragoudas; Gary Edd Fish; Yong Hao; Laurie Haynes; Jennifer I Lim; Ugo Menchini; Joan W Miller; Jordi Mones; Michael J Potter; Al Reaves; Philip J Rosenfeld; Andrew Strong; Xiang Yao Su; Jason S Slakter; Ursula Schmidt-Erfurth; John A Sorenson
Journal:  Retina       Date:  2004-02       Impact factor: 4.256

7.  Effects of verteporfin therapy on contrast on sensitivity: Results From the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation-TAP report No 4.

Authors:  Gary S Rubin; Neil M Bressler
Journal:  Retina       Date:  2002-10       Impact factor: 4.256

8.  Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.

Authors:  Keven J Blinder; Shannon Bradley; Neil M Bressler; Susan B Bressler; Guy Donati; Yong Hao; Colin Ma; Ugo Menchini; Joan Miller; Michael J Potter; Constantin Pournaras; Al Reaves; Philip J Rosenfeld; H Andrew Strong; Michael Stur; Xiang Yao Su; Gianni Virgili
Journal:  Am J Ophthalmol       Date:  2003-09       Impact factor: 5.258
  8 in total
  2 in total

1.  [Classification of biomedical research reports as a reference for evidence-based medicine in ophthalmology. A survey considering as example the journal Der Ophthalmologe].

Authors:  H P N Scholl; M Fleckenstein; T U Krohne; F G Holz
Journal:  Ophthalmologe       Date:  2005-12       Impact factor: 1.059

2.  [Diagnostics of metamorphopsia in retinal diseases of different origins].

Authors:  C Klatt; P Sendtner; L Ponomareva; J Hillenkamp; A Bunse; V-P Gabel; J Roider
Journal:  Ophthalmologe       Date:  2006-11       Impact factor: 1.059
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.